KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查 入排置信度 0.85

Topical Cannabidiol for Established Chemotherapy-Induced Neuropathy: A Pilot Randomized Placebo-Controlled Trial.

Stacy D'Andre, Paul Novotny, Camille Walters, Susie Lewis-Peters, Stephan Thomé, Cindy S Tofthagen, Karthik V Giridhar, Charles Loprinzi

Cannabis Cannabinoid Res 9(6) e1556-e1564

PMID39016024
PMCIDPMC11685298
DOI10.1089/can.2023.0253
发表日期2024-07-17
入排依据:The study is an oncology-related randomized trial with a drug intervention and reports original results, but it is explicitly a pilot trial (not Phase III/IIIb or definitive Phase II/III) and does not have a time-to-event efficacy endpoint.
摘要

摘要

Background: Patients have been known to use cannabinoids for treating established chemotherapy-induced peripheral neuropathy (CIPN) based on anecdotal information and retrospective reports suggesting that such might be beneficial. In response, a double-blinded, placebo-controlled, randomized, pilot clinical trial was developed to evaluate whether resultant data would support a phase III trial for testing whether a cannabidiol (CBD) cream might improve CIPN. Methods: Forty patients with established CIPN were randomized, in a double-blinded manner, to topical CBD or a placebo cream. The study product was applied for 2 weeks, followed by a crossover for 2 weeks. Neuropathy was evaluated using the European Organization of Research and Treatment of Cancer (EORTC)-CIPN20, the Chemotherapy-Induced Peripheral Neuropathy Assessment Tool, and the Global Impression of Change instruments. Side effects were recorded by symptom diaries. Results: The EORTC-CIPN20 scores were similar in the patients receiving CBD versus the placebo. Likewise, the toxicity scores were similar in patients who received the CBD versus the placebo. Conclusions: This pilot trial did not support that the studied CBD isolate cream improved painful established CIPN. It was well tolerated overall. Clinical Trial Registration Number: NCT05388058.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。